Drug interactions of Obeticholic

Warfarin:

Potential to decrease INR; monitor INR and adjust warfarin dosage as needed to maintain the target INR range.

CYP1A2 substrates with a narrow therapeutic index (e.g., theophylline, tizanidine):

May increase the exposure of CYP1A2 substrates; monitor the drug concentrations of CYP1A2 substrates with a narrow therapeutic index.

Bile salt export pump inhibitors (e.g., cyclosporine):

Avoid concomitant use.If co-administration is deemed necessary, monitor serum transaminases and bilirubin.

FDA，2022.02